RESUMEN
AIMS: Cardiovascular mortality remains high despite intensive treatment of people with Type 2 diabetes mellitus. Meta-analyses on rosiglitazone have raised concerns regarding its cardiovascular safety. We studied the effects of rosiglitazone on ultrasonic indices of carotid arterial disease and inflammatory markers in a group of Type 2 diabetic patients at high cardiovascular risk. METHODS: A trial of rosiglitazone in Type 2 diabetic patients with high cardiovascular risk and internal carotid artery plaque compared changes in carotid ultrasound intima-media thickness (IMT), plaque thickness, arterial stiffness and compliance, and inflammatory markers at baseline, 26 and 52 weeks. RESULTS: In the rosiglitazone group (n=28), carotid artery plaque thickness was reduced by 0.08 mm, compared with an increase of 0.19 mm (P=0.075) in the placebo group (n=29). There were no significant differences in changes of IMT, carotid wall compliance and stiffness between the two groups. Glycated haemoglobin reduced by -0.9 vs. 0.1% (-7 vs. 2 mmol/mol), (P<0.001); insulin resistance (HOMA-IR) reduced by -37.6 vs. -1.1% (P=0.016); and B cell function (HOMA-B) increased by 36.8 vs. 0.7% (P=0.009). Non-esterified fatty acids reduced by -23.5 vs. 7.9% (P=0.005); tissue plasminogen activator reduced by -25.0 vs. 0.6% (P=0.001); and plasminogen activator inhibitor activity reduced by -57.4 vs. -34.6% (P=0.052). CONCLUSIONS: Rosiglitazone reduced carotid artery plaque thickness, though not significantly, and there was no significant change in intima media thickness or other ultrasonic indices of carotid arterial disease. There were significant improvements in glycaemic control, insulin sensitivity and fibrinolytic, but not inflammatory, markers. There was no evidence in this study of any adverse effects on progression of carotid arterial disease.
Asunto(s)
Aterosclerosis/tratamiento farmacológico , Arteria Carótida Interna/efectos de los fármacos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Tiazolidinedionas/uso terapéutico , Adulto , Anciano , Aterosclerosis/diagnóstico por imagen , Arteria Carótida Interna/diagnóstico por imagen , Diabetes Mellitus Tipo 2/diagnóstico por imagen , Progresión de la Enfermedad , Femenino , Humanos , Resistencia a la Insulina , Masculino , Persona de Mediana Edad , Riesgo , Rosiglitazona , UltrasonografíaRESUMEN
BACKGROUND: Glycolysis is not completely or predictably inhibited by the glucose preservative currently in use, with glucose values falling by as much as 0.5 mmol/L during a 2-4-h period after sample collection. Immediate centrifugation of all samples is also impractical and therefore misdiagnosis of disease can occur, especially if more emphasis is being placed on fasting glucose for the diagnosis of diabetes. METHODS: Glycolysis at room temperature was evaluated over time using glyceraldehyde alone as well as in conjunction with standard antiglycolytic agents. RESULTS: Glyceraldehyde alone does not inhibit glycolysis completely. The combination of 11 mmol/L glyceraldehyde, 119 mmol/L sodium fluoride and 21.7 mmol/L potassium oxalate gave the best antiglycolytic results. The glucose values measured in samples stored at room temperature for 48 h was no different from those measured in samples centrifuged immediately after venepuncture and this is clinically superior to conventionally used sodium fluoride and potassium oxalate. CONCLUSION: Plasma glucose concentrations obtained from blood collected into tubes containing glyceraldehyde, sodium fluoride and potassium oxalate will more closely reflect those of the patient at venepuncture.
Asunto(s)
Glucemia/efectos de los fármacos , Glucólisis/efectos de los fármacos , Glucemia/metabolismo , Conservación de la Sangre/métodos , Recolección de Muestras de Sangre , Gliceraldehído/farmacología , Humanos , Fluoruro de Sodio/farmacología , Factores de TiempoRESUMEN
OBJECTIVE: To investigate the effects of the somatostatin analogue octreotide, which inhibits the release of various peptides, on 24-h ambulatory blood pressure profiles in subjects with primary (idiopathic) autonomic failure due to sympathetic denervation, and in particular to determine whether octreotide reduces daytime hypotension and whether it causes or accentuates nocturnal hypertension. SUBJECTS AND METHODS: Eighteen subjects with primary autonomic failure, confirmed by detailed physiological and biochemical autonomic tests, were studied in a randomized manner on two occasions, with and without octreotide treatment (1 mu g/kg body weight subcutaneously, twice a day at 0800 and 1800 h). Blood pressure was measured using the SpaceLabs 90207 system. This was connected at 0900 h with programmed recordings at 30-min intervals until 2300 h and at 60-min intervals until the next morning. There were additional subject-initiated recordings after 5 min each of lying, sitting and standing four times during the day, while sitting after lunch at noon and while standing following walking in the evening. Additional analyses included calculation of cumulative sum (cusum)-derived parameters and construction of cusum plots. RESULTS: After octreotide treatment, the overall mean daytime systolic/diastolic blood pressure (mmHg) was raised (123 +/- 2/77 +/- 1 without treatment versus 128 +/- 2/79 +/- 1 with treatment). There was a reduction in postural (supine versus standing: from 96 +/- 3/62 +/- 3 without treatment to 106 +/- 5/67 +/- 4 with treatment), postprandial (107 +/- 3/65 +/- 2 to 122 +/- 5/75 +/- 4) and exertion-induced (96 +/- 5/61 +/- 5 to 113 +/- 6/71 +/- 5) hypotension. Symptoms of hypotension were reduced by octreotide. Nocturnal blood pressure was lower after octreotide (139 +/- 3/84 +/- 1 versus 129 +/- 3/78 +/- 2). Analyses with the cusum technique further demonstrated blood pressure recovery during the day, with a reduction in the magnitude of change at night after octreotide treatment. CONCLUSIONS: In primary autonomic failure, 24-h ambulatory blood pressure profiles and cusum analyses indicate that octreotide has beneficial effects in reducing postural, postprandial and exertion-induced hypotension, without causing or increasing nocturnal hypertension.
Asunto(s)
Desnervación Autonómica/efectos adversos , Ritmo Circadiano/fisiología , Hormonas/uso terapéutico , Hipertensión/tratamiento farmacológico , Hipotensión/tratamiento farmacológico , Octreótido/uso terapéutico , Péptidos/efectos de los fármacos , Adulto , Monitoreo Ambulatorio de la Presión Arterial , Ejercicio Físico , Femenino , Humanos , Hipertensión/metabolismo , Hipertensión/fisiopatología , Hipotensión/metabolismo , Hipotensión/fisiopatología , Masculino , Persona de Mediana Edad , Péptidos/metabolismo , PosturaRESUMEN
1. The cardiovascular and catecholamine responses to supine leg exercise were measured in fifteen normal subjects (controls) and in three groups with sympathetic dysfunction: fifteen with central failure (Shy-Drager syndrome; SDS), fifteen with peripheral failure (pure autonomic failure; PAF) and two with isolated dopamine beta-hydroxylase deficiency (DBH deficiency). 2. With exercise, blood pressure increased in controls, fell markedly in SDS and PAF and was unchanged in DBH deficiency. After exercise, blood pressure rapidly returned to baseline in controls, but remained low in SDS and PAF. With exercise, heart rate increased more in controls than SDS or PAF; the response varied in DBH deficiency. 3. With exercise, cardiac output increased similarly in controls, SDS and PAF, with a larger increase in DBH deficiency. Vascular resistance fell less in controls than SDS, PAF and DBH deficiency. 4. With exercise, plasma noradrenaline increased in controls only; plasma adrenaline remained unchanged in all groups. In DBH deficiency, plasma noradrenaline and adrenaline were undetectable, but plasma dopamine was elevated and rose further with exercise. 5. Supine exercise substantially lowered blood pressure in sympathetic failure due to SDS and PAF. In DBH deficiency blood pressure was unchanged; this lack of fall may have been due to vasoconstriction induced by dopamine and other substances released from otherwise intact sympathetic terminals, or to preserved cardiac vagal function.
Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/fisiopatología , Catecolaminas/metabolismo , Ejercicio Físico/fisiología , Posición Supina/fisiología , Sistema Nervioso Simpático/fisiopatología , Adulto , Presión Sanguínea/fisiología , Catecolaminas/sangre , Dopamina/sangre , Dopamina beta-Hidroxilasa/deficiencia , Femenino , Frecuencia Cardíaca/fisiología , Humanos , Hipotensión , Pierna/fisiología , Masculino , Persona de Mediana Edad , Postura , Síndrome de Shy-Drager/fisiopatología , Temperatura , Factores de TiempoRESUMEN
We have studied beta-adrenoceptor number and affinity on peripheral blood mononuclear cells (PBMCs) in normotensives (NT) and hypertensives (HT), before and after intravenous administration of clonidine, an alpha 2-adrenoceptor agonist which lowers blood pressure predominantly by reducing central nervous system sympathetic outflow. After clonidine, there was a decrease in blood pressure and plasma noradrenaline (NA) and adrenaline (Ad) levels, with an increase in growth hormone (GH) levels, in both NT and HT. There was no difference in basal beta-adrenoceptor densities on PBMCs between NT and HT. After clonidine at 30 and 60 min, there was an increase in beta-adrenoceptor density associated with a low affinity in NT. In HT, no changes were observed. The increased beta-adrenoceptor densities on PBMCs in NT after clonidine, returned to baseline values after 2 h. Short term up-regulation of beta-adrenoceptors on PBMCs in NT after clonidine is accompanied by a fall in blood pressure (BP) and plasma levels of catecholamines. The changes may represent a compensatory mechanism reflecting a rapid externalization-activation of adrenoceptors residing on the internal surface of the membranes with a change of the coupling ability between the receptor and the catalytic component. In HT, although the haemodynamic and neurohormonal response to clonidine was similar to NT, short term upregulation of receptors did not occur. The lack of such response may mirror a form of regulatory dysfunction of beta-adrenoceptors in HT.
Asunto(s)
Encéfalo/fisiopatología , Clonidina/farmacología , Hipertensión/sangre , Monocitos/metabolismo , Receptores Adrenérgicos beta/metabolismo , Sistema Nervioso Simpático/fisiopatología , Anciano , Presión Sanguínea/efectos de los fármacos , Encéfalo/efectos de los fármacos , Epinefrina/sangre , Femenino , Hormona del Crecimiento/sangre , Humanos , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Norepinefrina/sangre , Valores de Referencia , Sistema Nervioso Simpático/efectos de los fármacosRESUMEN
There is a short-term up-regulation of beta-adrenoceptors on peripheral blood mononuclear cells (PBMC) after reduction of central sympathetic outflow by clonidine in normal individuals. We have studied beta-adrenoceptor number and affinity on PBMC in idiopathic Parkinson's disease (PD), pure autonomic failure (PAF), and multiple system atrophy (MSA; Shy-Drager syndrome) patients and age- and sex-matched normal controls (NC) before and after intravenous administration of clonidine, an alpha 2-adrenoceptor agonist which lowers blood pressure predominantly by reducing CNS sympathetic outflow. Basal beta-adrenoceptor density was high in PAF but within the normal range in PD and MSA patients. After clonidine there was a decrease in plasma levels of noradrenaline (NA) and adrenaline (Ad) in PD, MSA, and NC, and an increase in growth hormone (GH) in PD, PAF, and NC. NC. In PAF, NA and Ad remained unchanged. In MSA, there was no increase in GH levels. There was an up-regulation of beta-adrenoceptors on PBMC at 30 and 60 minutes after clonidine administration, which returned to baseline values after 2 hours, and the affinity of the receptors was decreased in NC and PD patients. Intracellular production of cAMP after isoproterenol stimulation demonstrated that the up-regulation was not functional. Up-regulation after clonidine did not occur in PAF and MSA patients. The observed correlation of plasma NA and sympathetic defect with basal and clonidine-induced up-regulation of beta-adrenoceptors on PBMC may provide insight into beta-adrenoceptor changes in other tissues and also help in differentiating subgroups of autonomic failure patients.
Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/fisiopatología , Clonidina/farmacología , Leucocitos Mononucleares/efectos de los fármacos , Enfermedad de Parkinson/fisiopatología , Receptores Adrenérgicos beta/efectos de los fármacos , Síndrome de Shy-Drager/fisiopatología , Adulto , Anciano , Enfermedades del Sistema Nervioso Autónomo/tratamiento farmacológico , Femenino , Humanos , Leucocitos Mononucleares/química , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/tratamiento farmacológico , Receptores Adrenérgicos beta/análisis , Valores de Referencia , Síndrome de Shy-Drager/tratamiento farmacológico , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiologíaRESUMEN
Short term regulation of beta-adrenoceptors in peripheral blood mononuclear cells after sympathetic activation has been previously documented in normal individuals but changes after a central reduction in sympathetic activity are not known. We have studied beta-adrenoceptor number and affinity on peripheral blood mononuclear cells in normal subjects, before and after intravenous clonidine, an alpha 2-adrenoceptor agonist which lowers blood pressure predominantly by reducing central nervous system sympathetic outflow. After clonidine there was a decrease in plasma levels of noradrenaline and adrenaline, and an increase in growth hormone. There was up-regulation of beta-adrenergic receptors on peripheral blood mononuclear cells 30 and 60 min after clonidine which was related to the fall in blood pressure, noradrenaline and adrenaline levels and to the increase in growth hormone levels. The affinity of the receptors was decreased. Return to baseline values was observed after 2 h. Intracellular production of cAMP after isoproterenol stimulation demonstrated that the up-regulation was not functional. Our studies indicate short term up-regulation of beta-adrenoceptors in peripheral blood mononuclear cells after clonidine. These observations after a reduction in sympathetic activity may be of importance if they mirror the pattern of redistribution of adrenoceptors, which are present in a wide range of tissues.